Accelerating Drug Discovery for Frontotemporal Degeneration

Sponsor: Alzheimer’s Drug Discovery Foundation

Deadlines:
Letter of Intent: May 20th, 2022
Invited Full Proposal: July 30th, 2022

Award: Through this program, AFTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), seeks to advance and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD. Funding can range from $100,000-$150,000 per year, average one year duration.